BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Henlius Therapy Wins Breakthrough Designation as First Immunotherapy Led Perioperative Regimen for Gastric Cancer

The first CDE-designated Breakthrough Therapy for perioperative gastric cancer, promising accelerated patient access. The world's first gastric cancer p...

November 21, 2025 | News

Guided Therapeutics Secures New LuViva Supply Agreement to Expand Cervical Cancer Screening Reach in China

Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, announced it had completed an initial supply agreement with Yuansh...

November 21, 2025 | News

Tsingke Biotech Showcases Breakthrough Speed in Protein and Antibody Development at PEGS Europe 2025

At PEGS Europe 2025, one of the industry's premier gatherings for innovation in protein and antibody engineering, Tsingke Biotech highlighted its latest ac...

November 20, 2025 | News

YolTech Therapeutics Receives FDA Clearance to Begin Pivotal Trial for In Vivo Gene Editing Therapy in PH1

YolTech Therapeutics, a clinical-stage biotechnology company developing next-generation in vivo gene editing therapies, today announced that the U.S. Food ...

November 20, 2025 | News

Shanghai Henlius and Organon Achieve FDA Approval for POHERDY, First Pertuzumab Biosimilar in the US

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) announced that the US Food and Drug Administration (FDA) has approved the Biologics...

November 19, 2025 | News

Lundbeck Moves Closer to Asian Launch of Vyepti with New Drug Application Accepted in Japan

Lundbeck's new drug application (NDA) for Vyepti® (eptinezumab) accepted by Japan's Ministry of Health, Labor and Welfare (MHLW), mark...

November 17, 2025 | News

SCIEX Expands China Footprint with Localized High Resolution Mass Spectrometry Platforms

SCIEX, a global leader in life science analytical technologies, announces the localization of its X500R QTOF system, ZenoTOF 7600 system, and ZenoTOF 7600+...

November 14, 2025 | News

Mabwell Secures NMPA Approval to Begin Phase II Trial of First-in-Class Anti-IL-11 Antibody for Pathological Scarring

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its novel anti‑IL‑11 monoclonal antibody...

November 12, 2025 | News

Sanyou Bio and Yugong Bio Forge Strategic Alliance to Advance High-End Synthetic Molecular Enzymes

Sanyou Bio and Yugong Bio today announced the signing of a strategic cooperation agreement. This powerful alliance marks a significant step ...

November 12, 2025 | News

Simcere Advances Treg-Selective IL-2 Mutant SIM0278 into Phase II Trial for Moderate-to-Severe Atopic Dermatitis

Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells (Treg) -preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278,...

November 11, 2025 | News

Harbour BioMed and Evinova Partner to Drive AI-Enabled Biologics Development

Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel anti...

November 10, 2025 | News

CorrectSequence Therapeutics Achieves World’s First Gene-Editing Success in Hyperlipidaemia Treatment

CorrectSequence Therapeutics' CS-121 Completed Dosing of First Chylomicronemia Patient, Demonstrating Excellent Safety and Significant Efficacy On&n...

November 07, 2025 | News

Mölnlycke Establishes First Wound Care Manufacturing Site in China to Strengthen Local Production and Supply Chain Resilience

Mölnlycke® Health Care, a global leader in MedTech, headquartered in Gothenburg, Sweden, is celebrating the commencement of its new wound car...

November 06, 2025 | News

Ailux and Eli Lilly Forge $345 Million AI-Driven Collaboration to Accelerate Bispecific Antibody Discovery

Ailux, an innovator in AI-powered biologics and a wholly owned subsidiary of XtalPi (2228.HK), a global leader in AI drug discovery, today announced a stra...

November 06, 2025 | News

Stay Connected